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Abstract
Thrombosis is a well-known side effect associated with Acute Lymphoblastic
Leukemia (ALL) treatment leading to significant morbidity rates. Thrombosis
occurrence in ALL patients seems to be due to the interaction between the disease,
the therapy and the possible inherited genetic defects affecting the hemostatic
balance. In this study we aimed to assess the prevalence of prothrombotic defectsFV Leiden, MTHFR (Methylene Tetra Hydrofolate Reductase enzyme) C677T &
prothrombin (PT) G20210A mutations in Egyptian pediatric ALL patients and its
impact on the risk of thrombosis onset as well as to evaluate the impact of the
presence of single versus multiple prothrombotic mutations on thrombosis. Sixty
three pediatric ALL patients with thrombotic event treated with ALL protocol
adopted from SJCRH (Saint Jude Cancer Research Hospital) study XV at the
Children’s Cancer Hospital in Egypt (CCHE) and 63 matched ALL control patients
were enrolled in the study. Restriction fragment polymorphism technique was used
to assess the prevalence of the FV Leiden and MTHFR C677T while Allele specific
PCR was used for Prothrombin G20210A. Our results showed that MTHFR C677T
prevalence between the ALL patients with and without thrombosis was 65% and
38.1% respectively p value = 0.002. The FV Leiden prevalence between the ALL
patients with and without thrombosis was 17.5% and 15.9 % respectively p value=
0.81. While the prothrombin G20210A prevalence was 3.2% in both groups. In
addition, patients who were older than 10 years or on SR/HR treatment protocol or in
induction treatment phase were also at high risk of thrombosis. The presence of
MTHFR C677T polymorphism can increase the risk of thrombosis 3 folds more than
those patients who didn’t have the polymorphism, while FV Leiden and PT
G20210A didn’t affect the thrombosis risk. Having more than one mutation didn’t
show a significant effect on increasing the risk of thrombus incidence (p= 0.087). We
concluded that MTHFR C677T is important risk factor for thrombosis in Egyptian
pediatric ALL patients. These results may help in the prediction of the thrombosis
susceptibility for ALL patients and a prophylaxis therapy may be considered before
having the thrombosis. To the best of our knowledge these findings regarding the
thrombosis risk factors in Egyptian pediatric ALL patients are first to be reported.
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1. Review of Literature
1.1 Acute Lymphoblastic Leukemia (ALL)
1.1.1 Incidence and Epidemiology
Acute Lymphoblastic Leukemia represent about 81% of pediatric leukemias
(Woo, Alberti, & Tirado, 2014). It is the most common cancer in pediatric patients
representing 25% of cancer diagnosed in pediatrics. ALL outcome is 90 % 5 years
overall survival which is very high rate of survival among different types of cancer
(Pui et al., 2013). The incidence of ALL in the United States is 35-40 new
case/million each year. There is a gradual increase in ALL incidence in the previous
25 years (Howlader et al., 2013).
At National Cancer Institute (NCI), Egypt, ALL constitutes 19.6% of all
childhood malignancies (Elattar et al., 2005), while the percentage of ALL cases
treated in Children’s Cancer Hospital of Egypt (CCHE) in the period between 20072012 was reported as 20% (1305/6240) of all pediatric cancer patients (CCHE 57357
Registry, 2012). There is a sharp increase in ALL incidences in age 2-3 years about
90 new case/million each year worldwide. This rate decreases to 30 case/million per
year by age 8 years. This high incidence of ALL among 2-3 years aged patients is 4 to
5 folds greater than that of infants and 10 years or older aged children (Howlader et
al., 2013). The incidence of ALL among white children is higher than that in black
children. There is about three-fold increase in ALL incidences in 2 - 3 years aged
white children than in black children. There is also a slight male predominance in all
age groups (Howlader et al., 2013).

1.1.2 Risk Factors for Developing ALL
There are varieties of risk factors associated with increased ALL risk; these
include X-rays exposure during prenatal stage, exposure to pesticides and ionizing
radiations. In addition, ALL occurs with higher frequency in patients with Bloom
syndrome, neurofibromatosis type I, ataxia-telangiectasia and Down syndrome. For
1

example, Down syndrome patients have a 20 fold increase in risk of ALL (Onciu,
2009).
On the other hand, there are factors with limited evidence to be a risk factor
for ALL. Few studies suggest a higher risk (1.5 fold) in case of paternal smoking
before pregnancy. Although some studies have reported increase in the ALL risk for
children who live near high voltage; other studies reported no risk association. In
addition to that few studies were done on the meat consumption in diet and showed
association with the increase in risk (Blot et al., 1999; Howlader et al., 2013).

1.1.3 Pathogenesis
ALL originates in the bone marrow from either the T or B lymphoblasts
(Figure 1). About 85% of pediatric ALL is B cell origin. The B cell origin ALL is
classified into several subtypes: pre-B ALL, common ALL and pro-B ALL. On the
other hand, T cell ALL represents 15% of pediatric ALL patients. Although T cell
ALL patients are characterized by resistance to chemotherapy in comparison with the
B cell ALL patients, the outcome of the ALL T cell approaches the B cell using risk
adapted therapy in many study groups (Pieters & Carroll, 2010).
Risk adapted therapy is therapy modification done according to the patient
predicted risk for relapse. Patients who have high risk criteria receive aggressive
therapy to prevent recurrence of the disease. While patients with good prognosis
receive effective therapy with fewer side effects and at the same time less aggressive
than that received by high risk (HR) patients. The factors used for the patients
stratification into different treatment arms are clinical and biological factors (Pieters
& Carroll, 2010).

2

Image adopted from http://www.cancer.gov/

Figure 1: A diagram showing the normal pathway for the differentiation of
blood stem cell. In normal healthy child, the Bone marrow produce immature cells called
blood stem cells, it can differentiate to either a lymphoid stem cell or a myeloid stem cell.
Myeloid stem cell differentiates into one of three blood cells which are; red blood cells,
platelets and white blood cells. While lymphoid stem cell can differentiate into one of three
types of white blood cells which are: B lymphocytes, T lymphocytes and Natural killer cells.

3

1.1.4 Clinical Presentation and Patients’ Outcome
Acute Lymphoblastic Leukemia is a bone marrow disease. The onset of ALL
is acute in most of the cases, although there are few cases that may evolve over
several months. Doctors can suspect ALL when there are symptoms of pancytopenia
(bone marrow failure). The most Common ALL signs and symptoms include bone
pain, pallor, bleeding, easy bruising and fatigue. Signs of extra medullary
involvement may appear in signs of intracranial pressure increase including headache.
In addition, physical examination may show hepato-splenomegaly and lymphadenopathy (Woo et al., 2014). Laboratory abnormalities may include hyper
leukocytosis, thrombocytopenia, leucopenia or neutropenia. Hyperleukocytosis
appears in 15% of pediatric ALL patients. Another important laboratory abnormality
is hyperuricemia that can result from tumor lysis (Onciu et al., 2009).
The pediatric ALL prognosis has improved over the last decades, where
therapy is adapted according to the patient’s level of relapse risk (low, standard and
high risk groups) and the patient’s response to chemotherapy. In addition, the
continuous appearance of new chemotherapeutic agents had a great role in improving
the outcome. The pediatric ALL patients’ outcome has dramatically increased from
10% in 1960 to a current 90% in many developed countries (Figure 2). The precise
risk assessment, improved supportive care and the optimal use of chemotherapeutic
agent have improved the 5 years disease free survival and the 5 years overall survival
rates to more than 85% and 90 % respectively in several treatment protocols (Pui et
al., 2013).

4

Image adopted from doi:10.1053/j.seminhematol.2013.06.007.
Figure 2: Survival assessed by Kaplan Mayer analysis for 2852 newly diagnosed
pediatric ALL patients’ in St. Jude children cancer hospital from 1962 to 2007.
During this time period, the patients have been treated by 15 different consecutive treatment
plans. Ten year free survival rates are shown in the above curve. The results show a drastic
improvement in patient outcome from 11.1% in the 1960’s to 91.1% in the early 20 th
century.
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1.2 Treatment
The ALL protocols of treatment consist of 3 main phases: induction of
remission, consolidation phase and maintenance or continuation phase. The typical
duration of the treatment is 2-3 years, according to which protocol is used. The goal
of the induction stage is to induce remission and restore the normal blood cell
production in bone marrow while the goal of the consolidation and the maintenance
phases are to eliminate residual disease and maintain the patient in remission. In
addition, chemotherapy can be injected intrathecally for central nervous system
(CNS) prophylaxis or treatment from the disease. There are different types of
antileukemic agents that are used for ALL treatment such as methotrexate, 6mercaptopurine, l-asparaginase, vincristine and glucocorticoids (Pieters & Carroll,
2010).

1.2.1 Asparaginase
In 1953, it was noted by Kidd that the serum of guinea pig has an antileukemic
effect in mice. Then it was discovered that the reason of the antileukemic effect was
the L-asparaginase enzyme in the serum, which leads to the asparagine amino acid
depletion and tumor regression. In 1970s, the L-asparaginase became one of the
important chemotherapeutic agents in ALL treatment protocols and the scientists
started to use it in the treatment protocols of ALL patients to achieve remission
(Rytting, 2012).
The use of L-asparaginase depends on the fact that the leukemic lymphoblasts
lack asparagine synthetase enzyme, which is essential for the synthesis of asparagine.
Therefore, it depends entirely on external asparagine supplies to grow. L-Asparaginase
enzyme results in the hydrolysis of asparagine amino acid producing ammonia and
aspartic acid. In effect, asparaginase enzyme results in the selective death of cancer
cells only due to depletion of asparagine amino acid. However, normal cells can
synthesize their own asparagine using asparagine synthetase enzyme. The asparagine
depletion causes an arrest in the cell cycle at the G1 phase as well as an impairment in
the cancer cell’s DNA, RNA and protein synthesis resulting in cancer cell death (Mu
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& Boos, 1998). Therefore, L-asparaginase enzyme results in the selective death of
cancer cells (Figure 3).
Asparaginase is given in induction and maintenance phases of total XV
protocol. In induction phase, the dose is 10,000 U/m2 taken intramuscular at days 6, 8,
10, 12, 14 and 16 of the induction phase. Three extra doses can be given on days 19,
21 and 23 if the patient residual leukemia cells at day 19 in the bone marrow are
greater than or equal 1%. While in the continuation phase, dose and regimen differs
according to the patient risk group. Low risk patients receive asparaginase on weeks 79 and 17-19, three doses of 10,000 U/m2/dose weekly. On the other hand, standard and
high risk patients receive 19 doses from week 1 till week 19, 1 dose weekly. Each dose
is 25,000 units /m2 taken intramuscular (Pui et al., 2009).

Image adopted from Critical Reviews in Oncology: Hematology 28 (1998) 97–113

Figure 3: L- asparaginase Mechanism of Action. L-asparaginase hydrolyzes
asparagine amino acid into ammonia and aspartic acid. In normal healthy cells, asparagine
can be synthesized from aspartic acid and glutamine using asparagine synthetase enzyme.
This enzyme is absent in Lymphoblastic leukemia cells so it depends on external asparagine
amino acid. Using L- asparaginase results in depletion of asparagine amino acid and
inhibition of protein synthesis in cancer cells.
7

1.2.2 Types of L-Asparaginase
There are three types of L-Asparaginase commercially available in the market
to date: asparaginase isolated from E.coli bacteria, Erwinia asparaginase extracted
from Erwiniac hrysanthemi bacteria and the PEG asparaginase which is the peglated
form of the E.coli asparaginase (containing polyethylene glycol) (Mu & Boos, 1998).
L- Asparaginase hypersensitivity manifests in the form of anaphylactic or allergic
reactions and can lead to the change to another asparaginase formulation in order to
achieve the best outcome and the least side effects.
The E.coli asparaginase is the native form of asparaginase as it is the oldest
one in the market. Its half-life is 1.2 days, which is a moderate half-life in
comparison with PEG and Erwinia asparaginase. If the patient has an allergic
reaction from E.coli asparaginase, he should be shifted to the Erwinia asparaginase.
The PEG asparaginase has a longer half-life than the native asparaginase.
This means a lower number of doses will be given to the patient and therefore better
patient compliance. Patients who have an allergic reaction from the peglated
asparaginase should be shifted to the Erwinia asparaginase (Asselin et al., 1993).
Erwinia asparaginase is used in patients have an allergy from both the
pegelated or the native asparaginase its half-life is 0.65 day which is shorter than the
peglated and the E.coli asparaginase. This short half-life result in increase the
number of asparaginase doses taken by the patient to get the asparagine depleted
(National Cancer Institute US, 2014; Rytting, 2012).
It has been shown that the use of Asparaginase in ALL protocols increase the
event free survival by 10% - 15% (Tong et al., 2014). Although the L-asparaginase is
considered an important antitumor drug in the treatment protocol of ALL patients as
it kills cancer cells without harming the normal body cells, L-asparaginase cause a
wide spectrum of adverse reactions to the patients. The L- asparaginase side effects
include severe allergic reactions, pancreatitis, hepatic dysfunction, hyperglycemia,
hemostatic system alterations which appear in the form of thrombosis, bleeding and
disseminated intravascular coagulation (DIC) (Pieters et al., 2012). In most of the
protocols, L – asparaginase is left out from the consolidation phase and administrated
8

only in the induction and maintenance phases. Asparaginase can be administered
either as an intramuscular injection or intravenous infusion (Rytting, 2012).

1.2.3 L-Asparaginase Side effects
Hypersensitivity
Hypersensitivity to asparaginase is one of the serious side effects that can
take place after asparaginase administration. The risk of hypersensitivity incidence
depends on prior administration of asparaginase and concomitant drugs in the
treatment regimen (for example, steroids). The incidence of hypersensitivity reaction
in ALL treatment protocols that include high dose corticosteroids in the induction
phase is not frequent (Rytting, 2012). On the other hand, hypersensitivity is more
frequent upon repeated administration of asparaginase without receiving steroids and
its occurrence ranges from 5%–10% (Rytting, 2012; Storring et al., 2009; Vrooman
et al., 2010). Although PEG-asparaginase cause less hypersensitivity than E.coli
asparaginase, it still can cause allergic reactions associated with repeated doses of
administration (Douer et al., 2007). Erwinia asparaginase can be used for patients
having hypersensitivity from E.coli and PEG- asparaginase, where there is no cross
reaction between E.coli and PEG- asparaginase antibodies and Erwinia asparaginase
(Rytting, 2012).

Pancreatitis
The three types of L-asparaginase preparations can result in pancreatitis. A
randomized clinical trial done on pediatric ALL patients using E.coli L- asparaginase
versus PEG L- asparaginase for standard risk patients showed no difference in
pancreatitis incidence rate between the two groups (Avramis et al., 2002). It was
shown that pancreatitis incidence associated with asparaginase in pediatric ALL
patients increase with patient age. This can give a hint that the pancreatitis incidence
in Adult will be higher than in pediatric patients (Kearney et al., 2009). Generally,
the pancreatitis incidence associated with asparaginase administration ranges from
5%–10% (Avramis et al., 2002; Fu & Sakamoto, 2007).

9

Thrombus Formation
Hemostasis is the mechanism where the body can control the bleeding from
injured blood vessels by clot formation. Then the body dissolves clots that no longer
needed. Blood clot is initiated from injury of wall vessel. Platelets accumulate
rapidly at the injury site followed by accumulation of coagulation factors forming a
clot. The coagulation factors are produced from a cascade of reactions to finally
produce fibrin. Fibrin will form a mesh between the platelets aggregation causing
clot stabilization. Any disturbance in the hemostatic system can result in excessive
thrombosis or bleeding (Horne, 2005).
Thrombus formation is a severe side effect that can takes place due to
asparaginase administration. It usually takes place in the early phases of treatment
and is related to different factors, such as central lines placement and
hypercoagulability due to leukemia activity. The incidence of thrombus formation
varies from 10% to greater than 30%. The incidence of thrombus increases with
older age. It was reported that the incidence of thrombosis is the same when E.coli
and Erwinia asparaginase are compared (Grace et al., 2011). The type of steroids
used in the induction therapy also can affect the incidence of thrombus where it was
reported that prednisolone is associated with higher incidence of thrombus (Durden
et al., 1983; Hernández-Espinosa et al., 2009; Nowak-Göttl et al., 2003).
Once thrombus diagnosis is confirmed, low molecular weight heparin is used
in the treatment of thrombus. Some studies showed the use of anti-thrombin III
infusion as a supportive coagulation therapy, but its role in decreasing the thrombus
incidence is not clear till now. A study was done on adult ALL patients showed a
decrease in thrombotic events when anti-thrombin III was used as prophylactic
infusion (Hunault-Berger et al., 2008). In order to avoid the L-asparaginase side
effects and improve the treatment outcome for ALL patients different trials were
tried, including using L-asparaginase from different sources and treatment schedules
modifications to optimize the L-asparaginase use in the therapy.
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1.3 Thrombosis in ALL
Although ALL disease has a very good outcome reaches to 90% 5 years
overall survival, the morbidity and mortality that result from toxicities of ALL
therapy are significant. These toxicities can lead to therapy modifications that will
affect the cure rate. Thrombosis is a well-known side effect associated with ALL
treatment protocol leading to significant morbidity rates. The fatality rate is about 15
% in those patients affected from thrombosis. The development of thrombosis can
interfere with the treatment plan of ALL patients thus affecting the ultimate outcome.
There are several studies that correlate the concomitant use of glucocorticoids and
asparaginase with increasing incidence of the thrombosis (Pui et al., 2013).

1.3.1 Incidence of Thrombosis in Children with ALL
Thrombosis in children in general is an infrequent incidence. In general
healthy pediatric population the incidence of pulmonary embolism (PE) and deep
venous thrombosis (DVT) is 0. 7–14 events / 100,000 children (Monagle et al., 2001;
Van Ommen et al., 2001). In comparison to the general estimates of thrombosis, the
ALL pediatric patients are considered to be at much higher risk for thrombosis. The
incidence of thrombosis in pediatric ALL patients ranges from 1.1% to 36.7% with
an average of 3.2%. This wide range of variation in the reported thrombosis
incidence is due to difference in the reported thrombosis definitions (asymptomatic
vs. symptomatic), different treatment protocols used and diagnostic tools used for
diagnosis and detection of the thrombosis (Athale & Chan, 2003a).
The designed studies for evaluating asymptomatic thrombosis reported much
higher thrombosis incidence when compared with other studies reporting
symptomatic thrombosis only. For example, a PARKAA study whose objective was
to compare ultrasonography to venography in the diagnosis of asymptomatic DVT in
pediatric ALL patients reported a 36.7 % incidence of thrombosis (Male et al., 2002;
Mitchell et al., 2003). On the other hand, other studies reported symptomatic
thrombosis incidence ranges from 2.8% to 14.3%. This shows the importance of
highlighting the thrombosis definition in the reported studies (Athale & Chan,
2003a).
11

In addition to the previous discussed factors, the chemotherapy schedule has
an important role in affecting the incidence of thrombosis incidence in pediatrics.
When 2 different chemotherapy protocols were compared, Berlin-Frankfurt-Munich
(BFM) and COALL protocols, it was found that although they treat the same ethnic
population and in the same time frame, the thrombosis incidence in patients receiving
BFM 90/95 protocol was 10 times higher than those receiving COALL 92/97
protocol. This difference in thrombosis incidence was due to difference of the
chemotherapy schedule in the 2 protocols (Mauz-Körholz et al.,2000; Nowak-Göttl
et al., 1999, 2001).

1.3.2 Locations of the Thrombotic Events in Children with ALL
The majority of thrombosis events in children are of venous origin; however
there are reports for thrombosis events of arterial origin. A large prospective metaanalysis of 17 studies examined the venous thromboembolism (VTE) in ALL
pediatric patients. The meta-analysis showed that symptomatic VTE was diagnosed
in about 50% of the patients in the central nervous system (CNS), where infarction or
stroke represents 18% and cerebral venous sinus thrombosis 28.6%. On the other
hand, the study reported other locations for VTE including right atrium (1%),
pulmonary embolism (1%), superﬁcial VTE (2.2%) and the lower limbs (7.7%)
(Caruso et al., 2006).
Central venous lines (CVL) are great tools that have been used for more than
20 years for children. It is used to maintain a venous access that facilitates the
administration of blood products, chemotherapy and other supportive care
medications. Central venous lines greatly improve the quality of life in pediatric
cancer patients. Although there are several advantages for the use of CVL, its use is
associated with both thrombosis and infections. Most thrombosis associated with
CVL is asymptomatic and located at the catheter entry site into the vein. The CVL
associated thrombosis occurs primarily in the upper venous system. It was reported
in a meta-analysis that the incidence of upper limb thrombus and CVL was 27.5%
(Caruso et al., 2006; Kenet et al., 2009; Mitchell et al., 2003).
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1.3.3 Effect of Age and Gender on the Development of
thrombosis
The incidence of VTE in ALL patients is high in patients greater than 1 year
and the incidence trend increase towards older children. On contrast, the VTE
incidence in the normal pediatric population is higher in the neonatal period and less
than 1 year of age (Athale et al., 2008; Caruso et al., 2006).
The gender effect on the development of thrombosis is unclear. While some of
the studies reporting gender distribution show female predominance or male
predominance other studies show equal distribution(Athale & Chan, 2003a). (Pui
et.al, 1985) reported male predominance in development of VTE. In contrast
(Gugliotta et al., 1992), (Priest et al., 1982) and (Nowak-Göttl et al., 1999) reported
female predominance.

1.3.4 The Main Risk Factors that Affect Thrombus Formation
in ALL Patients
The Thromboembolism occurrence in ALL patients seem to be due to the
interaction between the ALL disease, the therapy and the possible inherited genetic
defects affecting the hemostatic balance (Athale & Chan, 2003b) (Figure 4).

Risk Factor 1: Effect of Disease on Thrombosis
At diagnosis, there is evidence of increased thrombin generation in children
with ALL, the etiology of which is unclear. However, thrombosis in children with
ALL is most commonly reported after the initiation of anti-leukemic therapy
indicating a possible interaction of the disease and therapy (Athale & Chan, 2003b).
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Figure 4: shows the 3 main factors involved in thrombosis pathogenesis in ALL
patients. Development of thrombosis in ALL patients depends on the interaction between
three main factors. The disease itself can produce a procoagulant state cause the patient at
high risk of thrombus. The therapy can cause alteration in coagulation factors, in addition the
patient himself may have an inherited prothrombotic disorders that can affect the thrombosis
incidence susceptibility. In addition, other factors like having inflammation or central venous
line may affect the thrombosis incidence.
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Risk Factor 2: Effect of ALL Therapy on Thrombus
Formation
Asparaginase
Asparaginase is a corner stone in most of contemporary All treatment
protocols. However, L-asparaginase results in asparagine amino acid depletion,
which can impair the coagulation cascade by reduction in coagulation factors and or
inhibitors (Rizzari et al., 2014).

Glucocorticoids
It was found that glucocorticoids administrated concomitantly with
asparaginase in ALL patients can affect the inflammatory reactions by inhibitory
effects. The inhibitory effects can be divided into early and late effects. The
glucocorticoids early effects are inhibition of capillary dilatation, inhibition of
developing edema, as well as deposition of fibrin while late effects are proliferation
of fibroblasts, capillary proliferation and collagen deposition. On the other hand, it
was found that dexamethasone is more efficient in protection against thrombotic
event versus prednisolone and that was explained by a stronger anti-inflammatory
glucocorticoid effect (Goodman A & JG, 2001).
A prospective multicenter study was done on pediatric ALL patients treated
according to BFM protocol to assess the risk of symptomatic thrombus incidence in
patients receiving either prednisolone or dexamethasone. The thrombus frequency in
the prednisolone group was 10.4% while in the dexamethasone group was 1.8%. This
study concluded that the use of dexamethasone instead of prednisolone in the
induction phase can significantly reduce the thrombus onset in ALL pediatric
patients (Nowak-Göttl et al., 2003).
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Risk Factor 3: Effect of Inherited Thrombophilia on the
Development of Thrombosis
Blood coagulation is an important mechanism that protects our body from
bleeding. The key enzyme of the coagulation system is the thrombin enzyme. It
converts fibrinogen to fibrin to form the fibrin mesh which occludes the vascular
injury and has a feedback effect for the amplification of the coagulation process. The
adequate amount of thrombin at injury sites results from a cascade of reactions called
coagulation cascade. It is triggered by endothelium injury which led to blood
exposure to the extravascular tissue. In normal conditions, there is a harmony
between the procoagulant system, which induce coagulation and the anticoagulant
system which controls its effect. Any disturbance in this natural balance due to
genetic or acquired reasons may lead to thrombotic or bleeding diseases (Dahlbäck,
2000). Most of the factors that alter an individual’s thrombosis risk are related to an
alteration in the normal balance that exists between the procoagulant and the
anticoagulant state.
Regulation of the blood coagulation process is important in order to prevent
its generalized or continuous activation, which can lead to thrombus formation. The
coagulation system must be active only in case of injury and for sufficient time to
control bleeding by the formation of a fibrin clot. In order to achieve this balance,
there are a number of regulatory mechanisms that are activated in order to control the
effect of activated coagulation factors such as FIXa, FXa, FVa and FVIIIa. There are
anticoagulant cofactors and proteins responsible for binding to the activated
coagulation factors to limit their activity, for example, protein C, protein S and antithrombin. Anti-thrombin inactivates many activated coagulation factors such as
thrombin, FIXa, FXa and TF-VIIa complex. Protein S acts as a cofactor for activated
protein C (APC) forming a protein S/APC complex. This complex is able to
inactivate FVa and FVIIIa, which are responsible for the conversion of the inactive
prothrombin to thrombin, and thus in effect the S/APC complex controls thrombin
production (Dahlbäck, 2000; Norris, 2003).
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Thrombophilia refers to a group of conditions that make an individual more
susceptible for having clots than normal. Inherited thrombophilia (IT) can affect
ALL patients’ thrombus incidence risk and may be used as a predictive tool for
thrombus prevention. Although it is an important risk in thrombus formation;
however it is still not clear till now how the thrombophilia screening will help in
decreasing the thrombus incidence rate (Revel‐Vilk et al., 2003).
A classification system for inherited prothrombotic defects divided these
conditions into two groups. Group 1 disorders: hereditary deficiencies of anticoagulation factors (Anti thrombin III deficiency, protein C deficiency and protein S
deficiency). Group 2 disorders: hereditary disorders associated with the increase in
the levels or function of coagulation factors (Factor V Leiden, PT gene mutation,
elevated level of homocysteine, elevated levels of lipoprotein (a), elevated levels of
factors VIII, IX and XI) (Athale & Chan, 2003b).
It was reported in literature that inherited thrombophilia has an important role
in increasing thrombus risk in ALL patients. A prospective multicenter study was
done on patients treated on treatment protocol BFM 90/95 to assess the risk of
thrombus in pediatric ALL patients. The study showed that the thrombus risk was
much higher in patients with inherited thrombophilia defect (46.5% vs. 2.2%, P <
0.001). In addition, thrombus risk was higher in patients with multiple inherited
thrombophilia defects when compared to those with single inherited thrombophilia
defect (P =0.009) (Nowak-Göttl et al., 1999). In contrast, PARKAA study reported
no correlation between inherited thrombophilia defects and thrombus formation
(Mitchell et al., 2003).
A meta-analysis concluded that inherited thrombophilia can increase the risk
of thrombosis by 8 folds (Caruso et al., 2006). There is a current debate in the field
regarding the role of inherited thrombophilia (IT) on the incidence of thrombosis in
ALL patients and its importance as a predictive tool for asparaginase-related
thrombus formation. This debate and difference in results is due to different
treatment protocols used and the different populations with ethnic variability. That is
why it is important to screen ALL pediatric patients in the Egyptian population for
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inherited thrombophilia in order to examine its role on asparaginase-related thrombus
formation.

IT Factor 1: Factor Five Leiden
Factor V is a coagulation factor whose active form is known as FVa. FVa has
an important role in the production of thrombin from the inactive prothrombin.
Therefore, an increase in the levels of FVa will lead to an increase in thrombin
production resulting in a hyper coagulopathy state. Normally, Activated protein C
(APC) has an inhibitory effect on factor V and thus an inhibitory effect on the
conversion of prothrombin to thrombin. However, it was found that in some patients,
factor V will show resistance against APC and will not be inactivated. This was later
found out due to a point mutation in the FV gene, referred to as FV Leiden mutation
(Norris, 2003). This mutation results in the replacement of arginine with glutamine at
codon 506 and thus a loss of one of the three APC cleavage sites in factor Va which
leads to an impaired ability of APC to degrade factor Va resulting in the Activated
protein C resistance phenomena (Dahlbäck, 2000).
In 1993, it was reported as unusual phenomena while studying the effect of
adding external activated protein C (APC) to venous thromboembolism (VTE)
patient’s plasma. They were expecting slowing down in the coagulation process upon
adding the APC, as FV will be inactivated. However, they noticed that in some
patients the slowdown of the coagulation process did not occur and they called this
phenomena as APC resistance (Carlsson & Svenssont, 1993). After one year, another
team of researchers discovered a point mutation in FV gene where Guanine is
replaced by Adenine at position 1691of exon 10 of the gene. This mutation was
called FV Leiden according to the city they were doing their research in. This point
mutation causes a change in the amino acid coding for arginine at codon 506
changing it to glutamine (Bertina et al., 1994). Because of this change in the FV gene
the APC enzyme cannot recognize the FV effectively and the FV remains active
causing hyper coagulopathy state. This lead to interruption for one of the most
important regulatory pathways in the coagulation cascade which may be a risk factor
for VTE (Jadaon, 2011a).
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Since the discovery of the FV Leiden, many studies were done to know the
prevalence of FV Leiden in patients with VTE and healthy populations. It was found
that Factor V Leiden has high prevalence in Europe especially in the Caucasian
population. Factor V Leiden prevalence in healthy Caucasian population is (1-15%)
while in patients with VTE is (15-65%). On the other hand, FV Leiden prevalence in
other ethnic groups like Africans, Japanese, Chinese, and South-East Asians is
almost rare. It was suggested that the FV Leiden mutation first occurred in an old
ancestor of the European Caucasian population (Jadaon, 2011a). The highest
prevalence of the FV Leiden mutation is found in Europe; especially in Germany,
Sweden and Cyprus. It is also common in Saudi Arabia (Rees, 1996).

IT Factor 2: Prothrombin Gene Mutation
Prothrombin has an important role in the coagulation cascade. Blood
coagulation is initiated by a blood vessel injury then a biochemical cascade starts to
block the injured vessel by a blood clot. The coagulation cascade consists of a large
number of proteins and enzymes called coagulation factors. Thrombin is an
important coagulation factor produced in the liver in an inactive form, known as
prothrombin. Prothrombin circulates in the blood stream till it is activated, as in the
case of a blood vessel injury for example. Prothrombin at this point is activated to
thrombin by a coagulation factor called factor X. Thrombin is essential for the
formation of a fibrin clot by converting fibrinogen (factor I) to fibrin, thus leading to
the blockage of the injured blood vessel by a mesh like structure (Jadaon, 2011b).
In 1996, it was reported by Poort et al. that the prothrombin gene G20210A
mutation is a cause for venous thrombosis. Prothrombin G20210A mutation results
in increased levels of prothrombin in plasma causing a higher risk of thrombus
formation (Poort et al., 1996). Prothrombin G20210A gene mutation is a point
mutation. This point mutation involves a replacement of an adenine with guanine at
20210 position on prothrombin 3' untranslated region (3' UTR) (Pollak, Lam, &
Russell, 2002). A study investigated the effect of the G20210A mutation on the
mRNA and protein expression of prothrombin. The study reported that this mutation
affects the polyadenylation site of the prothrombin gene, increasing prothrombin
mRNA and protein synthesis, with a subsequent increase in prothrombin plasma
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levels(Ceelie et al., 2004). An increase in prothrombin production thus leads to a
higher tendency for clot formation. This condition is called hyper coagulopathy,
whereby a patient will be at a higher risk of thrombus formation than normal, by 2
folds (Poort et al., 1996).
Prothrombin G20210A mutation has a prevalence of 2% in white Caucasian
population (Atasay et al., 2003). It is more prevalent in Southern European than in
Northern European. It is rare in people from Asian and African descent (Rosendaal et
al., 1998). Individuals with a G20210A mutation suffer from an increased risk of
thrombosis by 2-3 folds (Bounameaux & Rosendaal, 2011).

IT Factor 3: Elevated Level of Homocysteine
Homocysteine (Hcy) is an intermediate product produced from methionine
conversion to Cysteine. Homocysteine in normal circumstances is catabolized into
cysteine by transulfuration pathway or can be processed back to produce methionine
amino acid by remethylation pathway (Figure 5). Hyper homocysteinaemia results
from MTHFR polymorphism. Methylene tetra hydrofolate Reductase (MTHFR) is an
important enzyme in folate metabolism. In addition, it is a cofactor in homocysteine
re-methylation process to produce methionine. Therefore, reduction in MTHFR
enzyme cause increase in homocysteine plasma level. There are 2 common genetic
polymorphisms associated with low function of MTHFR gene: MTHFR A1298C and
MTHFR C677T (Athale & Chan, 2003b). The MTHFR C677T polymorphism takes
place in exon 4 resulting in substitution of Alanine to Valine at codon 222 (Tantawy
et al., 2010).
Hyper homocysteinaemia can also result from other factors like methotrexate
chemotherapy (antifolate medication), vitamin B12, folate, vitamin B6 deficiencies
(Girling, 2001). It was found that an elevated homocysteine plasma level is an
independent risk for venous thrombosis and arteriosclerotic vascular disease. The
exact mechanism of thrombosis associated with high homocysteine plasma level is
unknown (Athale & Chan, 2003b; Crowther & Kelton, 2003).
MTHFR C677T polymorphism is associated with high levels of fasting Hcy
plasma levels. This mutation is a risk factor for thrombosis development especially in
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case of folate deficiency (Frosst et al., 1995). There is a high variation in MTHFR
polymorphism among different population. In Asia and Europe, there is a north to
south increase gradient, while in the sub Saharan African population the mutation
prevalence is very low. On the other hand, there is a high prevalence of this mutation
in the Mediterranean region (Bauduer & Lacombe, 2005). The prevalence differs in
different ethnic groups and ranges from 2% to 54.5% (G.Pepe et al. 1998).

1.3.5 Inherited Thrombophilia in Cancer Patients
There are several studies done on FV Leiden, MTHFR C677T and
Prothrombin G20210A mutations to investigate their role as a risk factor for
thrombus in cancer patients but the results appear controversial (Akın et al., 2012;
Haim et al., 2001; Mitchell et al., 2003; Otterson et al., 1996; Ramacciotti et al.,
2003; Ravin et al., 2002). This difference in results between different studies may be
due to a difference in population under study and/or there may be other factors in the
coagulation cascade having a role in synergistic the hyper coagulopathy effect of the
studied mutations.
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Figure 5: Shows the normal mode of action of MTHFR enzyme. In normal
metabolism, homocysteine (Hcy) is converted to methionine via a trans- methylation reaction
in the presence of methionine synthetase, which catalyses the transfer of a methyl group from
5-methyltetrahydrofolate to homocysteine forming methionine and tetrahydrofolate. On the
other hand, Hcy is converted in a certain proportion to Cysteine through transsulfuration
pathway. MTHFR convert 5, 10- methylene-tetrahydrofolate to 5 methyl tetrahydrofolate
(5MTHF) ensuring continuous supply of 5MTHF and thus allowing the production of
methionine. MTHFR polymorphism affects the Hcy re methylation process and result in
increase in homocysteine plasma level. In addition, 5,10- methylene-tetrahydrofolate act as
methyl group donor which allow the conversion of (dUMP) to deoxthymidine monophosphate
(dTMP) in the presence of thymidylate synthase enzyme result in DNA synthesis.
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1.4 Aim of the Work
As more insight should be gained in the field of thrombophilia, it becomes
important to re-examine this old problem in the context of the pediatric Egyptian
ALL patients. This will enable us to identify patients at risk for thrombosis, and may
help to develop therapeutic and/or preventive strategies.
The main objectives of this study were:
1. To assess the prevalence of prothrombotic defects (FV Leiden, MTHFR C677T
and prothrombin G20210A mutations) in Egyptian pediatric ALL patients.
2. To estimate the impact of inherited Thrombophilia (IT) on the risk of thrombosis
onset in pediatric ALL patients that can guide therapy modification and thromboprophylaxis, if indicated.
3. To evaluate the impact of the presence of single versus multiple IT prothrombotic
mutations on thrombosis.
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2. Subjects and Methods
2.1 Subjects
Sixty three pediatric ALL patients with thrombotic event ( age more than 1
year & less than 18 years old at diagnosis) treated with ALL protocol adopted from
SJCRH study XV for low or standard/high risk at the Children’s Cancer Hospital in
Egypt (CCHE) during period between August 2009 and September 2013. While the
control group included 63 ALL patients without thrombotic event treated at CCHE
with same protocol and matched for age, gender, IPT and risk stratification.
Subjects were excluded if they were:
- Non-Egyptian ALL patients.
- Their ages were less than one year or greater than 18 years at diagnosis.
- Patients with Down syndrome or having other syndromes to avoid any other
factors that may affect their risk of thrombosis.

The ethical committee of CCHE and the American university in Cairo approved
the study and a written informed consent was obtained for each patient’s guardian
according to the guidelines of the Helsinki declaration.
After the patient had got thrombosis, he is treated with Low molecular weight
heparin with a therapeutic dose till the thrombus become stationary or recanalized
followed by prophylactic dose. Radiological diagnosis and assessment is done by
using Doppler flow in cases of DVT & MRI +/- MRV in case of brain thrombosis to
check thrombosis status. Clinical data collected included: patient’s age at diagnosis,
gender, risk stratification, Immunophenotyping, initial TLC and patients’ outcome.
Number of L-asparaginase doses before event, treatment modifications, site of
thrombus, symptoms and complications associated with thrombus and either the
patient was rechallenged with L-asparaginase after the event or not was also collected.
Acute Lymphoblastic Leukemia patients were treated according to Saint Jude
Total XV protocol without the up-front window phase ( Pui et al., 2009). They were
subjected to initial work-up to confirm ALL diagnosis which included: CBC at
diagnosis, bone marrow examination, immunophenotyping (IPT), DNA index,
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molecular translocations, cytogenetic karyotyping (Coustan-smith et al., 2000). The
treatment protocol started with remission-induction phase (42 days) in which patients
received prednisone, L-asparaginase (E.Coli), cytrabine, doxorubicin, vincristine, 6mercaptopurine and cyclophosphamide. According to patient initial characteristics
and response at remission date (Day 42), each patient was assigned to low risk (LR),
standard risk (SR), or high risk (HR) at the end of induction. Consolidation phase (8
weeks) followed the induction period, consisted of four cycles of HD-MTX given
every other week. Then L asparaginase continued again in continuation phase, where
for SR/HR patients they receive weekly L Asparaginase till Week 19, While LR
patients received L asparaginase every other day (3 doses /week) on weeks7-9 and
weeks 17-19. Continuation phase lasted for 146 weeks for boys and 120 weeks for
girls (Pui et al., 2009).

2.2 Blood sampling
All the forthcoming procedures were performed at the molecular biology unit
at the laboratory department, CCHE-57357. Blood samples (2-5ml each) were
withdrawn from patients. Tubes containing disodium ethylene diamine tetra-acetic acid
(EDTA) were used (Diagnostics, Franklin Lakes, NJ, USA).

2.3 DNA Extraction
DNA was isolated from peripheral blood to study the selected genes. DNA was
extracted using Gene JET Genomic DNA Purification Kit (Thermo scientific, #K0721)
in accordance to the manufacturer instructions. The isolated DNA concentration was
measured using NanoDrop spectrophotometer (NanoDrop 2000, USA). The O.D (optical
density) was measured at wavelength A260nm and A280nm.

2.4 MTHFR C677T gene genotyping
Detection of MTHFR C677T mutation was performed by PCR-RFLP
technique (restriction fragment length polymorphism). Primers, restriction enzyme and
fragments obtained are presented in table 1 (Tantawy et al., 2010).
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Table 1: Primers, restriction enzyme and fragments produced from MTHFR
C677T gene digestion.
Restriction enzyme Restriction
Fragment
Gene
Primer sequence
condition
Parameter
MTHFR
C677T

Forward primer
5’TGAAGGAGAAG
GTGTCTGCGGGA3’

HinfI fast digest
(10U/1µl)
(Thermo scientific,
FD0804)

Reverse primer:
5’AGGACGGTGCG
GTGAGAGTG 3’

1µl at 37°C
for10
minutes.

Wild type: 198
base pair.
Heterozygous:
198, 175, and
23 base pair.
Homozygous:
175 and 23
base pair.

The amplification was done using [8 x 11 cm (Bio-Rad mini sub cell® GT
712Br)]. The total volume for the PCR reaction was 25 µl, and the components of
each reaction were: 1 µl extracted DNA (50 ng/1µl), 0.25µl (1 unit) DFS-Taq DNA
Polymerase, (BIORON, Germany), 2.5 µl10X Buffer, 2.5 µl (10 mM) Deoxynucleotide
triphosphates (dNTPs) (Thermo Scientific, #R0181), 1.25µl (10 µM) MTHFR F primer,
1.25µl (10 µM) MTHFR R primer (Table 1), then 16.25 µl PCR Water was added to
complete the reaction volume to 25µl.
The PCR conditions for MTHFR gene amplification were: initial denaturation
at 95oC for 2 minutes, followed by 40 cycles of: denaturation (94oC for 15 sec),
annealing (72oC for 15 sec) and extension (72oC for 30 sec). Then final extension step
at 72oC for 1 minutes. An aliquot (5 µl ) from the PCR product was run on 2%
agarose gel (Lonza) at 100 volt for 20 minutes against a DNA ladder Gene Ruler 100 bp
(Thermo Scientific, #SM0241) to check the presence of the amplified product.
The MTHFR amplicon was 198 bp fragment. The amplicon was digested using
sequence depending endonuclease fast digest enzyme [HinfI] (1 µl/10 U, 37°C for 10
minutes). Digested fragments were visualized on UV trans illuminator after vertical
electrophoretic separation (Bio-Rad Mini-PROTEAN® 3 cell 525 BR) at100 V for 120
min. on a 15% acrylamide gel. Digestion of the amplicon for MTHFR C677T gene
polymorphism yielded bands of 198 bp in CC wild type, 175 bp, 23bp in TT
homozygotes, and all 3 bands (198, 175, and 23 bp) in CT heterozygotes (Figure 6).
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Figure 6: The digestion of DNA by HinfI enzyme in case of normal and mutant
MTHFR C677T alleles. The MTHFR C677T polymorphism creates a restriction site for
HinfI digest enzyme. The digestion of the PCR product showed production of 198 bp in CC
wild type. Heterozygous allele produced 3 bands: 198, 175 and 23 bp. Homozygous allele
produced 2 bands: 175 bp, 23bp.

2.5 Factor V Leiden gene genotyping
Detection of Factor V Leiden was performed by PCR-RFLP technique
(Abdullah et al., 2010). Primers, restriction enzyme and fragments obtained are
presented in Table 2.
Table 2: Primers, restriction enzyme and fragments produced from FV Leiden
gene digestion.
Gene
Primer sequence
Restriction
Restriction Produced
Mutation
enzyme
condition
Fragments size
FV
Leiden
G1691A

Forward primer:
GGA ACA ACA
CCA TGA TCA
GAG CA -3'
Reverse primer:
5' TAG CCA GGA
GAC CTA ACA
TGT TC -3'

5'

MnII fast
digest
(10U/1µl)
(Thermo
scientific,
FD1074)
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1µl at
37°C
for10
minutes.

Wild type:
157, 93 and 37 bp
Heterozygous:
157, 130, 93 and
37 bp.
Homozygous:
157 and 130 bp

The amplification was done using [8 x 11 cm (Bio-Rad mini sub cell® GT
712Br)]. The total volume for the PCR reaction was 25 µl, and the components of
each reaction where: 2.5 µl 10X Buffer, 2.5 µl (10 mM) Deoxynucleotide triphosphates
(dNTPs) (Thermo Scientific, #R0181), 1.25µl (10 µM) FV F primer, 1.25µl (10 µM) FV
R primer (Table 2), 1 µl extracted DNA (50ng/1 µl), 0.25µl (1 unit) DFS-Taq DNA
Polymerase (BIORON,Germany) then 16.25 µl PCR Water was added to complete the
reaction volume to 25µl.
The PCR conditions for FV gene amplification were: initial denaturation at
94 oC for 2 minutes, followed by 40 cycles of: denaturation (94 oC for 15 sec),
annealing (55oC for 15 sec) and extension (72 oC for 30 sec). Then final extension
step at 72 oC for 1 minutes. An aliquot (5 µl) from the PCR product was run on 2%
agarose gel (Lonza) at 100 volt for 20 minutes against a DNA ladder Gene Ruler 100 bp
(Thermo Scientific, #SM0241) to check the presence of the amplified product.
The presence of FV Leiden mutation removes the MnII digest enzyme
restriction site. The FV amplicon size was 287 bp fragment. The amplicon was digested
using sequence depending endonuclease fast digest enzyme [MnII] (1 µl/10 U, 37°C for
10 minutes). Digestion of the amplicon for FV Leiden gene polymorphism yielded bands
of 3 fragments: 157 bp, 93 bp, and 37 bp in GG wild type while157bp, 130 bp in AA
homozygotes, and all 4 bands 157, 93, 130and 37bp in GA heterozygotes (Figure7). The
digested fragments were visualized on UV Trans illuminator after vertical
electrophoretic separation (Bio-Rad Mini-PROTEAN® 3 cell 525 BR) at100 V for 120
min. on a 15% acrylamide gel.
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Figure 7: The digestion of DNA by MnII in case of normal and mutant FV
alleles. The presence of FV Leiden mutation removes the MnII digest enzyme restriction
site. The PCR product digestion showed production of 157, 93 and 37 bp bands in case of
wild type. In case of heterozygous alleles, 157, 130, 93 and 37 bp bands were produced,
while homozygous allele showed 157 and 130 bp bands.

2.6 Prothrombin G20210A genotyping
Detection of PT G20210A mutation was performed by Allele specific PCR
Technique (ASPCR). For each patient 2 reactions were performed one reaction
containing the mutation primer while the other reaction contains wild type primer. FIX
primers were used in both reactions to detect factor IX gene as an internal control
(Ranguelov et al., 2002). The primers used in amplification of the PT gene are shown in
Table 3.
The ASPCR is a modified technique of standard PCR that allows efficient SNPs
discrimination. Where 2 forward (Mutation or wild type primer) and 1 reverse primers
(common) are used in 2 different tubes. Where Tube M contains the entire reaction
component without the wild type primer and it is supposed to detect if the patient has
SNP. Normally, if the patient is normal only the internal control band will appear at
219 bp in this lane. While tube N contains the entire reaction components except the
Mutation primer, this reaction is supposed to detect if the patient has a wild type
allele or not. If the patient is heterozygous or wild type a band will appear at 340 bp
29

plus the internal control band. While if the patient is homozygous only the internal
control band will appear at 219 bp (Figure 8) (Ranguelov et al., 2002).
Table 3: Primers used in PT G20210A Allele Specific PCR
Primer

Sequence

PT Reverse
(Common)

5’-TCT AGA AAC AGT TGC CTG GCA G-3’

PT Forward
(WT)

5’-GCA CTG GGA GCA TTG AGG ATC-3’

PT Forward
(Mutant)

5’-GCA CTG GGA GCA TTG AGG ATT-3’

FIX-Forward

5’-CTC CTG CAG CAT TGA GGG AGA TGG ACA TT-3’

FIX-Reverse

5’-CTC GAA TTC GGC AAG CAT ACT CAA TGT AT-3’

The amplification was done using [8 x 11 cm (Bio-Rad mini sub cell® GT
712Br)]. The total volume for the PCR reaction was 25 µl, and the components of
each reaction where: 1 µl extracted DNA (50ng/1 µl), 0.25µl (1 unit) HOT FIRE POL
hot start DNA Polymerase (SolisBioDyne,01-02-00500 ), 2.5 µl 10X Buffer B1
(Without MgCl2 or detergent), 2.5 µl (10mM) Deoxynucleotide triphosphates (dNTPs)
(Thermo Scientific , #R0181), 2.5 µl (25 mM) MgCl2, 1.25µl (10µM) PT Common
primer Table 3, 1.25µl (10µM) PT wild primer (N reaction only), 1.25µl (10µM) PT
Mutation primer (M reaction only), 1.25µl (10µM) FIX- Forward primer, 1.25µl (10µM)
FIX- Reverse primer then 11.25 µl PCR Water was added to complete the reaction
volume to 25µl.
The PCR conditions for PT gene amplification were: initial denaturation at
95 oC for 10 minutes, followed by 10 cycles of: denaturation (94 oC for 30 sec),
annealing (60oC for 30 sec) and extension (72 oC for 60 sec). Then repeat the
following steps for 25 cycles: 30 seconds at 94 °C, 30 seconds at 55 °C and 1 minute
72°C. Then final extension step was run at 72 oC for 7 minutes. Twelve µl from each
PCR product was run on 2% agarose gel (Lonza) at 100 volt for 30 minutes against a
DNA ladder Gene Ruler 100 bp (Thermo Scientific, #SM0241) to check the presence of
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the amplified product.

Figure 8: Prothrombin Allele Specific PCR expected bands in both M and N
lanes. M lane represents the PCR product when the mutant forward primer was used, while
N lane represents the PCR product when the wild type allele forward primer was used. The
wild type allele shows 340 and 219 bp bands in the N lane while 219 bp band only produced
in the M lane. The heterozygous allele shows 340 and 219 bp bands in both lanes N and M.
The homozygous allele shows 219 bp band in N lane while 340 and 219 bp bands produced
in M lane.

2.7 Statistical Methods
Data was analyzed using IBM SPSS advanced statistics version 20 (SPSS
Inc., Chicago, IL). Numerical data were expressed as mean and standard deviation or
median and range as appropriate. Qualitative data were expressed as frequency and
percentage. Chi-square test or Fisher’s exact test was used to examine the relation
between qualitative variables. For not normally distributed quantitative data,
comparison between two groups was done using Mann-Whitney test (nonparametric t-test). Survival analysis was done using Kaplan-Meier method and
comparison between two survival curves was done using log-rank test. Odds ratio
(OR) with it 95% confidence interval (CI) were used for risk estimation. All tests
were two-tailed. A p-value < 0.05 was considered significant.
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3. Results
One hundred twenty six ALL patients were enrolled in this study and divided
into 2 groups. The 1st group included patients with thrombus and the 2nd group is the
control group. Patients descriptive data were collected from the hospital medical
records (archived files and electronic medical records) for both control and thrombus
groups.
Out of a total 889 Egyptian patients treated with ALL protocol (age more
than 1 year and less than 18 years old at diagnosis) adopted from SJCRH study XV
for low or standard/high risk at the Children’s Cancer Hospital in Egypt (CCHE)
during period between August 2009 and September 2013, 84 patients had thrombus.
There were 8/84 patients died with no sample, 6/84 patients refused to participate,
1/84 lost follow up, 1/84 had Marfan syndrome and 5/84 were down syndrome. The
final number of thrombus patients enrolled in the study was 63/84.

3.1 Patients' characteristics
In both groups the patients age, Gender, initial total leukocyte count (TLC),
immunophenotyping (IPT) and risk at diagnosis were comparable (Table 4). The
patients were divided according to age into 3 subgroups, from 1 to less than 5 years,
from 5 to less than 10 years and from 10 to 18 years.
In thrombus group, the patients’ age trend was higher in the sub group from
10-18 years (52.4%) in comparison to the other 2 sub-groups. Most of the thrombus
patients were diagnosed as standard/high risk (80.9%) while the low risk patients
were 19%. The Male patients represented 69.8% of the total thrombus group. The
initial TLC was less than 100 x103/ml in 85.2% and the immunophenotype was
(68.3%) of B cell origin.
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Table 4: Clinical characteristics of the enrolled patients with and without
thrombus
Cases
Control
N (%)
N (%)

Age at diagnosis
(years)

0.536
Mean = 9.4
11 (17.5)
19 (30.2)
33 (52.4)

Mean = 8.8
11 (17.5)
19 (30.2)
33 (52.4)

Mean = 38.5
52 (85.2%)
9 (14.8%)
2

Mean = 63
51 (81%)
12 (19%)
NA

Male
Female

44 (69.8%)
19 (30.2%)

43(68.3%)
20 (31.7%)

Low Risk
Standard Risk
High Risk

12 (19%)
44 (69.8%)
7 (11.1%)

15 (23.8%)
40 (63.5%)
8 (12.7%)

Immunophenotype
43 (68.3%)

44 (69.8%)

1-<5
5-<10
10-18

Initial TLC (103/ml)
< 100
>=100
Missing

P Value

0.524

0.847

Gender

0.744

Risk

B cell
B Precursor
undifferentiated
C-ALL

0 (0%)

1 (1.6%)

26 (41.3%)

28 (44.4%)

Pre-B

14 (22.2%)

14 (22.2%)

Pro-B

3 (4.8%)

1 (1.6%)

20 (31.7%)

19 (30.2%)

T early

11 (17.5%)

7 (11.1%)

T intermediate

7 (11.1%)

11 (17.5%)

T late

0 (0%)

1 (1.6%)

T cell
undifferentiated

2 (3.2%)

0 (0%)

T cell
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0.847

3.2 Thrombus Timing
In 42/63 patients (66.7%) the incident took place during the induction phase
while 21/63 patients (33.3%) had the incident during the continuation phase. The
incident here is thrombus ± infarction (Table 5). Thrombosis that occurred between
the first dose of asparaginase and the last dose of asparaginase at week 19 was
included in the analysis.

3.3 Number of Doses Before the Thrombosis
The L-asparaginase doses taken before the incident were classified into 3
groups: 1- 4 doses, 5-9 doses and greater than or equal 10 doses. Seventeen patients
(26.9%) had from 1 to 4 doses before the event, 26/63 patients (41.2%) had from 5
to 9 doses before the event, 20/63 patients (31.7%) had greater than 10 doses before
the event (Table 5).

3.4 Treatment Modifications
Out of the 63 patients with thrombosis 47 patients (74.6%) had treatment
modifications and the rest continued the treatment protocol smoothly. The number of
patients who skipped L-asparaginase doses was 43 (68.3%) while four patients had
delayed treatment without omitting doses (Table 5).

3.5 Rechallenge with L - Asparaginase After Thrombosis
In the thrombosis group, 56/63 patients (88.9%) were rechallenged
(restarted) with L- asparaginase after the event and 7/63 (11.1%) patients stopped Lasparaginase for the rest of the protocol. Progression took place in 15 rechallenged
patients (15/56 = 26.7%), while 41/56 patients (73.2%) continued the L –
asparaginase smoothly. Asparaginase was rechallenged after diagnosis of thrombosis
with a median duration of 10 weeks (Table 5).
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Table 5: Characteristics of pediatric ALL thrombus group
Cases
N (%)

Type of incidence
Thrombus only
Thrombosis with infarction
Hemorrhagic infarction
Non hemorrhagic infarction

58 (92.1%)
5 (7.9%)
2/5
3/5

Treatment phase at time of the event:
42 (66.7%)
21 (33.3%)

Induction
Continuation

Number of L-Aspara doses before event

Median =6 (Min=1& Max=28)

1-4 doses

17 (26.9 %)

5-9 doses

26 (41.2%)

≥10 doses

20 (31.9 %)

Treatment Modifications
16 (25.4%)
47 (74.6%)

No
Yes
Delayed Aspara doses
Number of patients
Duration (days)

4/63 (6.3%)
(Median =14,Min.= 4 & Max=49 )

Omitted Aspara doses
Number of patients
Number of doses omitted:

43/63 (68.3%)
(Median =3.5, Min=1 & Max=17 )
28/43 (65.1%)
7/43 (16.2 %)
8 /43 (18.6 % )

1-4 doses
5-9 doses
10-17 doses

Rechallenge of L-asparaginase
7 (11.1%)
56 (88.9%)

No
Yes
Progression on rechallenge:

41/56 (73.2%)
15/56 (26.8%)

No
Yes
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3.6 Outcome and prognosis
Symptoms associated with the thrombus included headache 52%, convulsions
21.3%, blurred vision (8%), vomiting (8%), lower limb Swelling and pain (9.3%.)
and dysphagia due to laryngeal paralysis (1.3%) (Table 6). On the other hand, about
10% of the thrombus patients were associated with comorbid complications such as
hemiplegia, hypotonicity and tremors that lasted with the patient for 18 months
(Table 5). Those patients with comorbid complications were associated with CNS
thrombosis. The Event free survival (EFS) is the duration from the start of treatment
till relapse or death, while the overall survival (OS) is the duration from the start of
treatment till death. With a median follow up of 22.4 months, the 36 months OS was
89.8% ± 10.2 and 85.4 ± 13.5 for patients with and without thrombosis respectively,
while the EFS was 86.7% ± 10.3 and 81.7 ± 13.3 for patients with and without
thrombosis respectively. There was no significant difference in the OS (P = 0.91) and
EFS (P =0.85) when comparing patients with and without thrombosis (Figure 9 and
10).
Table 6: Symptoms and comorbidities in the studied pediatric ALL thrombus
patients

Symptom or complication
Symptoms *

Frequency (%)

Headache

39/75 (52%)

Convulsions

16/75 (21.3%)

Vomiting

6/75 (8%)

Blurred vision

6/75 (8%)

laryngeal paralysis

1/75 (1.3%)

Swelling &pain

7/75 (9.3%)

Comorbidity
57 (90.5%)
6 (9.5 %)

No
Yes
Hemiplegia

3 (4.8%)

Hypotonia

1 (1.6%)

Tremors

1 (1.6%)

Unstable convulsions

1 (1.6%)

*Most of patients had more than 1 clinical symptom associated with the incident, where 53
patients had 75 symptom associated with the thrombosis. No data for 10 patients regarding
symptoms associated with event.
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Figure 9: Overall survival (OS) of the thrombosis group compared to nonthrombotic group. The 3 years OS for the non-thrombus and thrombus patients was 85.4
± 13.5 and 89.8% ± 10.2, respectively. No significant difference in OS between the 2 groups
(P = 0.91).
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Figure 10: Event free survival (EFS) of the thrombosis group compared with
the non-thrombotic group. The 3 years EFS for the non-thrombus and thrombus patients
was 81.7 ± 13.3 and 86.7% ± 10.3, respectively. No significant difference in EFS between
the 2 groups (P =0.85).
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3.7 Site of thrombosis
Most of the patients had more than 1 clot at different sites. A total of 79 clots
were diagnosed in the 63 patients with thrombosis. The most common sites of
thrombosis were central nervous system (CNS) (n=55), upper venous system (n=17)
and lower limb (n=7). Patients with a CNS site of thrombosis had either a cerebral
venous sinus thrombosis or infarction. On the other hand, those with an upper
venous system site of thrombosis had the clot in either the internal jugular vein
and/or the superior vena cava (Table 7).
Table 7: Site of thrombus in 63 pediatric ALL patients
Site of VTE
Thrombosis sites
N=79*
55 (69.6%)

CNS

50 (63.3%)
5 (6.3%)

Sinus venous thrombosis
Thrombosis with infarction

17 (21.4%)

Upper venous system:

16 (20.2%)
1 (1.2%)

Internal jugular vein
Superior Vena Cava
Lower limb

7 (8.8%)

Total

79 (100%)

*79 clots were diagnosed in 63 patients
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3.8 MTHFR C677T Genotyping
Presence of a C677T mutation creates a new restriction site for HinfI in the
amplified MTHFR PCR product resulting in 2 fragments (175 bp, 23 bp). On the
other hand, its absence results in the PCR product remaining intact (198 bp). The
digestion of the PCR product showed production of 198 bp in CC wild type.
Heterozygous allele produced 3 bands: 198, 175 and 23 bp. Homozygous allele
produced 2 bands: 175 bp, 23bp (Figure 11). Our results showed that, in the case
group 22/63 patients (34.9 %) were wild type allele, 36/63 patients (57.1%) were
heterozygous allele and 5/63 patients (7.9 %) were homozygous allele (Table 8). On
the other hand, in the control group 39/63 patients (61.9%) were wild type allele,
18/63 patients (28.6 %) were heterozygous allele and 6/63 patients (9.5 %) were
homozygous allele. There was a significant difference between patients with and
without thrombosis (P=0.002) with odds ratio 3.028 and 95% confidence interval
(CI) (1.465-6.258).

Figure 11: MTHFR PCR product digestion using HinfI Fast digest enzyme on
15 % acrylamide gel. Patients can either be wild type (one band; 198 bp) (lane 4-9),
heterozygous (3 bands; 198, 175, 23) (lane 10) or homozygous C677T (2 bands; 175, 23 bp)
(lane 3), in addition the 23 bp band not detected on the gel.
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3.9 FV Leiden Genotyping
Presence of a FV mutation abolishes a restriction site for MnII enzyme in the
amplified FV PCR product resulting in 2 fragments (157 bp, 130 bp). On the other
hand, its absence results in 3 fragments (157, 93 and 37 bp). The PCR product
digestion showed production of 157, 93 and 37 bp bands in case of wild type. In case
of heterozygous alleles 157, 130, 93 and 37 bp bands were produced, while
homozygous allele showed 157 and 130 bp bands as shown in figure 12. Our results
showed that in thrombus patients, 52/63 patients (82.5 %) were wild type allele,
10/63 patients (15.9%) were Heterozygous allele and 1/63 (1.6 %) was homozygous
allele. On the other hand, in the control group 53/63 patients (84.1%) were wild type
allele, 9/63 patients (14.3 %) were heterozygous allele and 1/63 patient (1.6%) was
homozygous allele. Comparing the 2 groups showed no significance difference (P
= 0.811) (Table 8).

Figure 12: FV Leiden PCR product digestion using MnII Fast digest enzyme on
15 % acrylamide gel. Patients can either be wild type (3 bands; 157, 93 and 37 bp) (lane
2-5&7), homozygous (2 bands; 157 and 130 bp) (not shown in this figure) or heterozygous
(4 bands; 157, 130, 93 and 37 bp) (lane 1, 6).
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3.10 Prothrombin G20210A Genotyping
The expected produced bands in case of wild type allele G/G will be 219 bp
in M lane while in N lane will has 219 bp and 340 bp in N lane, the Homozygous
A/A allele will produce 219 bp and 340 bp in M lane and 219 bp band in N lane,
while the heterozygous allele G/A will produce 219 and 340 in both lanes (Figure
13). Our results showed that out of the 63 patients with thrombus 61 patients (96.8
%) were wild type allele, 2 patients (3.2%) were heterozygous allele and there was
no homozygous allele detected. On the other hand, in the control group 61 patients
(96.8 %) were wild type allele, 2 patients (3.2 %) were heterozygous allele and there
was no homozygous allele detected. There was no significant difference detected
between patients from both groups (Table 8).

Figure 13: Prothrombin G20210A allele specific PCR products on agarose 2%
gel. Each patient had 2 adjacent lanes (M and N). The M lane represents the PCR product
containing the Mutant allele primer, while N lane represents the PCR product containing the
wild type allele primer. Wild Type allele (lane 2, 3, 5, 6) showed 340 and 219 bp bands in
the N lane while 219 Bp band only produced in the M lane. The heterozygous allele (lane4)
showed 340 and 219 bp bands in both lanes N and M.
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3.11 Combined Genes
Having more than one mutation didn’t show a significant effect on
increasing the risk of thrombus incidence (p= 0.087) Table 8.
Table 8: Shows the prevalence of the studied genes among patients in the case
and control groups.
Cases
N (%)

Control
N (%)

Factor V Leiden

P Value
0.811

Wild

52 (82.5%)

53 (84.1%)

Mutant;

11 (17.5%)

10 (15.9 %)

Heterozygous

10/63 (15.9%)

Homozygous

1/63

(0.439 -2.86)

1/63 (1.6%)

MTHFR C677T

0.002

Wild

22/63 (34.9 %)

39/63 (61.9 %)

Mutant:

41/63 (65 %)

24/63 (38.1 %)

36 /63 (57.1%)

Homozygous

5/63

1.121

9/63 (14.3%)

(1.6%)

Heterozygous

OR (CI 95 %)

3.028
(1.465-6.258)

18/63 (28.6 %)

(7.9 %)

6/63

(9.5 %)

*

PT G20210A
Wild

61/63 (96.8 %)

61/63 (96.8 %)

Mutant:

2/63

2/63 (3.2 %)

(3.2 %)

Heterozygous

2/63

Homozygous

0

(3.2 %)

2/63

*
(3.2 %)

0

Combined genes

0.087

(Multiple traits)

3.12
(0.852-10.647)

No mutation

17/63 (27%)

32/63 (50.8%)

Single mutation

38/63 (60.3% )

26/63 (41.3%)

2 mutation

8/63 (12.7%)

5/63 (7.9% )

* No p value because of small number of cases within sub groups.
.
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4. Discussion
The thrombus risk in ALL patients is thought to arise from idiopathic
generation of thrombin at diagnosis associated with decrease in the inhibitory effect
of anti-thrombin due to depletion by asparaginase in addition to other risk factors
(Payne & Vora, 2007). In this study, we examined 63 ALL pediatric patients with
thrombosis and 63 matched non thrombus patients. Our main objective was to
identify the main risk factors for thrombosis in Egyptian pediatric ALL patients. Up
to our knowledge there were no reports about the risk factors for thrombosis in this
population of patients. Since the genetic factors mainly depend on ethnicity so it is
important to study those risk factors in Egyptian population in addition to the clinical
factors.

4.1 Patients Gender, Age, IPT and Risk Stratification as
Risk Factors for Thrombosis
The current study showed that the thrombosis incidence was higher in SR and
HR patients than LR patients. Out of the 63 patients with thrombosis, 81% were
SR/HR while 19% were LR. These results are consistent with other investigators
reports, in a study conducted on patients treated with Total XV study protocol
thrombosis incidence was reported to be higher in SR and HR patients. Out of 36
patients with thrombosis 86% of the patients were standard and high risk while
13.8% of the patients were low risk (Pui et al., 2009). In addition, It was reported that
the frequency of SR/HR patients among pediatric ALL patients in Egypt was 57.4%
(Sidhom et al., 2013). There was a higher frequency of SR/HR patients in the current
study thrombus patients when compared to what was reported by Sidhom et al 2013.
This higher frequency can implicate the importance of considering the Risk
stratification as a risk factor for thrombosis incidence.
In addition, it was found in the current study that patients greater than 10
years old had a higher incidence of thrombosis. Where the percentage of patients
with age greater than 10 and less than or equal 18 was 52.4%, while the percentage of
patients from 1 year to less than 5 years and from 5 years to less than 10 years was
found to be 17.5% and 30.2% respectively (Table 1). Similarly, it was reported that
age group greater than 10 years was associated with higher risk of thrombus in Total
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XV study protocol ( Pui et al., 2009). The same results were reported by Dana-Farber
cancer institute protocols results from 1991 to 2008 (Grace et al., 2011). This was
explained by the delayed dexamethasone clearance in older patients. In addition, it
had been shown that older pediatric ALL patients have both decreased fibrinolysis
and decreased anticoagulant factors when compared to younger patients receiving the
same therapy (Appel et al., 2008; Pui et al., 2009; Yang et al., 2008). On the other
hand, it was reported that the percentage of Egyptian pediatric ALL patients with age
greater than 10 years was 25% (Sidhom et al., 2013). This difference in patients’ age
distribution between the current study thrombus patients and what was reported by
Sidhom et.al 2013 indicates that there may be an important role for age as an
important risk factor for thrombosis.
The patients gender was analyzed in the current study thrombus group, the
males’ frequency in the thrombus group were 70% while 30% were females. These
results are consistent with what was reported before regarding male predominance in
acquiring thrombosis in ALL patients (Pui et al., 1985). On the other hand, Sidhom
et al. 2013 reported male frequency was 60% while female was 40% in pediatric
ALL patients. The current study showed a slight higher frequency of males in the
thrombus patients when compared to what was reported by Sidhom et.al 2013. This
indicates that males may have higher risk for thrombosis.
The immunophenotyping results of the current study thrombus patients
showed 68.3% of the patients were B cell and 31.7% T cell precursor. This is
consistent with what was reported regarding a higher frequency of T cell precursor
in the thrombus ALL patients in comparison with those without thrombosis (26% vs.
10%) (Grace et al., 2011). On the other hand, Sidhom et al. 2013 reported 75.8% of
the studied patients were B cell precursor while 24.2% were T cell precursor. This
slight increase in T cell frequency in thrombus patients may indicate it as risk factor
for thrombosis.
Based on what we demonstrated in this study, it is clear that both the age
greater than 10 years and SR/HR patients have a significant higher risk of thrombus
incidence more than others. While both males and T cell patients have a slight higher
risk than the other patients.
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4.2 Number of L-Asparaginase Doses Given Before
Thrombosis
In the current study, patients were divided into 3 groups according to the
number of L - Asparaginase doses received before the thrombosis incidence. The
number of patients who had thrombus after receiving 5 to 9 L - Asparaginase doses
(41.2%) was higher than the other 2 groups. This may have an implication of
increase thrombosis risk after the 5th to the 9th dose of L - Asparaginase due to the
accumulation of doses till the end of the induction phase which contains 6 or 9 doses
of L - Asparaginase according to the disease risk. In addition to the number of
accumulated asparaginase in induction phase, there are other thrombosis risk factors
as the prednisolone glucocorticoids and the hyper-coagulopathy associated with the
disease. On the other hand, the patients who received L - Asparaginase greater than 9
doses have dexamethasone glucocorticoid administrated concomitantly which is
characterized by less risk of inducing thrombosis than prednisolone. Furthermore,
the hyper-coagulopathy state of the patient from the disease becomes lower than in
the induction phase (Nowak-Göttl et al., 2003).

4.3 Time of Thrombus Incidence as a Risk Factor for
Thrombosis
The current study results showed that 66.3% of the thrombosis incidence took
place in induction phase while 33.3% of the patients had the thrombosis in
continuation phase. Similarly, other investigators reported that the majority of
thrombosis incidents took place in the induction phase of the treatment protocol
(Payne & Vora, 2007). In a retrospective study, it was reported that 90% of the
thrombosis incidence in ALL patients treated on BFM-90 German protocol occurred
during the induction phase.
The higher incidence of thrombosis during the induction phase in comparison
with the rest of treatment phases was explained by different factors, where the
disease is still highly active with high thrombin production and a high burden of
lymphoblast cytolysis. In addition, the treatment is highly intense during induction
containing a combination of concurrent administration of glucocorticoids and L46

asparaginase (Sutor et al.,1999). On the other hand, patients in the post induction
phases have less cell lysis and treatment intensity (Caruso et al., 2006). Another
reason for high incidence of thrombosis in induction is the type of treatment used in
the protocol. Total XV treatment protocol used in this study is applying prednisolone
glucocorticoids in the induction phase. It was reported in a study comparing 2 BFM
studies that the risk of thrombosis during induction was much higher with
prednisolone than dexamethasone (thrombosis frequency in BFM90/95 prednisolone
=10.4% while BFM 2000 dexamethasone =1.8 % p=0.028) and this is consistent
with the current study results (Nowak-Göttl et al., 2003). This higher incidence of
thrombosis in induction phase indicates the importance of considering patients in
induction phase at higher risk of thrombosis than others.

4.4 Rechallenge with L – Asparaginase After Thrombus
Incidence
In the current study, 88.9% of the patients with thrombus were rechallenged
with L – Asparaginase, out of those patients 28.3% were progressed. Grace et al. 2011
confirmed that L -Asparaginase can be rechallenged in cancer patients with
thrombosis. The rechallenging of thrombus patients with L - Asparaginase might be
needed to achieve high EFS and OS in these patients. In DFCI protocols (1991-2008),
Grace et al. 2011 reported that out of the 27 pediatric patients who got thrombus 74%
of patients were rechallenged. The progression on rechallenge was 20% of the
rechallenged patients in that study and this is comparable with what was demonstrated
by our study. The guidelines used by Grace et al. 2011 to rechallenge patients with LAsparaginase were to closely monitor anti-FXa levels and imaging should
demonstrate thrombus improvement or stabilization before rechallenging. In addition,
he recommended 4 weeks from incidence before rechallenging patients with the LAsparaginase. He reported median of 9 weeks from incidence before rechallenging
patients with the L-Asparaginase for pediatrics and 4 weeks for adults in DFCI
protocols. While in the current study, the median duration from thrombus till
rechallenge was 10 weeks that is comparable with DFCI protocols results. It is
important to mention that the thrombus patients in the current study was rechallenged
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with L-Asparaginase once the thrombus is stationary or showed partial recanalization
in order to achieve the best patients’ outcome.

4.5 Prognosis and Outcome of Patients with Thrombosis in
Comparison to Control Patients
In the current study, there was no significant difference between EFS (P
=0.856) or OS (P= 0.912) of the thrombus patients and those patients in the control
group. This comparable EFS and OS between the 2 groups may be explained by the
high percentage of rechallenged patients (88.9%) in the current study, which means
less number of missed L - Asparaginase doses and better adherence to the treatment
protocol. In addition, a study was done by Grace et al. 2011 presenting the results of
Dana-Farber protocols from 1991 to 2008 showed that the thrombus history didn’t
affect the patient prognosis. In his study, the EFS and OS rates in patients with
thrombus were similar to those in patients treated with the same treatment protocol
but without thrombus. This was explained by the guidelines followed to rechallenge
asparaginase and avoid asparaginase discontinuation which negatively affect the EFS
and OS. On the other hand, it has been reported that thrombus patients had a lower
EFS than those patients treated with the same protocol and did not have thrombosis.
This was explained by early asparaginase discontinuation (Hunault-Berger et al.,
2008; Ku et al., 2009). Based on the similar OS and EFS rates in patients from the
thrombus and the non-thrombus group of the current study, we can conclude that
following a strict guidelines in resuming L- Asparaginase after thrombosis incidence
is very important for enhancing thrombus patients survival.

4.6 Site of Thrombosis
It was found in the current study that the most common thrombus site was the
cerebral sinuses (69.6%) followed by upper venous system (21.4%) while the CVL
use did not have an effect on the thrombus formation in the current study. Similarly,
it was reported that cerebral venous sinus thrombosis has high prevalence in ALL
pediatric patients followed by upper venous system thrombosis and lower limb
(Payne & Vora, 2007). A review done on symptomatic thrombosis in pediatric ALL
between 1966 and 2003 reported that 50% of the incidence was CNS and 50% non48

CNS (Athale & Chan, 2003a). In addition, a meta-analysis done on 17 studies having
1752 pediatric ALL patients reported that out of 91 events 53.8% were in CNS
(Caruso et al., 2006). However, it was reported in the results of DFCI that the most
common site is the upper limb and the CVL associated thrombus followed by the
sinus venous thrombus and lower limb (Grace et al., 2011). This difference in results
between the current study and the DFCI results can be explained by our limited use
of CVL when compared to the other institution in ALL patients.

4.7 Comorbidities and Symptoms
Thrombosis in ALL Patients

Associated

with

The present study showed that the most common clinical symptoms
associated with sinus thrombus were headache (52%), convulsions (21.3%). On the
other hand, the lower limb DVT presented commonly with pain and swelling (9.3%).
These symptoms are similar to those described in previous studies (Grace et al.,
2011; Payne & Vora, 2007).
Comorbidity is a long lasting complication associated with the patient, in the
current study it is associated with the patients due to thrombosis. We found in the
current study that 10.7% of patients with CNS thrombosis suffered from
comorbidities in the form of hemiplegia, long lasting tremors, unstable convulsions
and hypotonicity. Usually the comorbidity of thrombosis is associated with CNS
thromboembolism. It was reported that 15–20% of patients with CNS thrombosis are
associated with comorbidities which appear in the form of hemiparesis, aphasia or
having residual neurological deficits (Athale & Chan, 2003a). It is important to
notice that comorbidities associated with thrombosis did not affect the patients’
treatment plan only but also it affects the patients’ quality of life as it causes long
term complications to the patients.

4.8 Inherited Thrombophilia
Thrombosis

as

a

Risk Factor

for

The inherited thrombophilia role as risk for thrombosis in cancer patients is
controversial. There are studies that reported no association between the FV Leiden,
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Prothrombin G20210A and MTHFR C677T and risk of thrombosis, while others
reported an association between those mutations and thrombosis incidence in cancer
patients. The variability in association of those mutations to thrombosis risk factors
was a great motivation to start the current study in Egyptian pediatric ALL patients.

4.8.1 FV Leiden and PT G20210A
The current study was a case control one and it was done on 2 groups of
Egyptian pediatric ALL patients. Each group had 63 patients matched in sex, disease
risk and age group. The results showed that the prevalence of FV Leiden mutation in
thrombus group was 17.5 % while it was 15.9 % in the control group. There was no
significant difference between both groups in FV Leiden mutation P value = 0.81.
The prothrombin G20210A mutation prevalence in the current study showed no
significant difference between the 2 groups. The 2 groups almost have the same PT
G20210A prevalence which was 3.2 %. No homozygous allele was detected for PT
G20210A only heterozygous. These results are consistent with other investigators
findings, where a study done to evaluate the VTE risk on gynecologic oncology
patients concluded that FV Leiden is not a risk factor for VTE incidence (Ravin et
al., 2002). Another study done on 135 Turkish pediatric leukemia patients showed
that 10.3% of the patients had FV Leiden mutation while 5% had prothrombin
G20210A mutation. Out of the 135 patients 3 had thrombosis and none of the 3
patients had FV or prothrombin mutation. This study suggested that there is no
association between FV and Prothrombin G20210A mutation and risk of thrombosis
in leukemia pediatric patients (Akın et al., 2012). In addition, a prospective study
done on 211 cancer patients in Brazil, patients were divided into 2 groups with and
without thrombosis to investigate the role of FV Leiden and PT G20210A in
thrombosis risk. FV Leiden was found with a frequency of 2.7% and 1.5% in the
control and thrombus group respectively. Prothrombin G20210A was found in 1.3%
and1.5% of control group and the thrombus group respectively. This study concluded
that FV Leiden and PT G20210A don’t have a significant role in the risk of
thrombosis in patients with different types of cancer (Ramacciotti et al., 2003).
Finally, a prospective cohort study done by PARKAA group on ALL pediatric
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patients suggested that there was no correlation between the FV Leiden or
prothrombin G20210A and the risk of thrombosis (Mitchell et al., 2003).
In contrast to the previous studies, other studies showed that FV Leiden,
Prothrombin G20210A mutations have an important role in increasing the risk of
thrombus in cancer patients. As example, a study done on cancer patients showed
that PT G20210A was a significant risk factor of VTE (Kennedy et al., 2005).
Another study was done on 80 ALL pediatric patients reported the presence of FV
Leiden and prothrombin 16.3% and 4% respectively in patients without thrombosis.
While 50% of the patients with thrombosis had Prothrombin G20210A mutation
(Harlev et al., 2010). In a prospective study, researchers showed that there was a
significant thrombosis risk associated with inherited thrombophilia traits in pediatric
ALL patients. This prospective study was done on 289 ALL patients. It was found
that 58/289 patients were associated with inherited thrombophilia trait. While 27 out
of the 58 patients (46.5%) with at least 1 inherited thrombophilia trait developed
thrombosis compared to 5/231 (2.2%) patients without inherited thrombophilia trait
(Nowak-Göttl et al., 1999).

4.8.2 MTHFR C677T
In the current study, MTHFR C677T mutation prevalence was found to be
highly significant in the thrombus group when compared to the control group with
P value = 0.002. The prevalence of MTHFR C677T mutation in the thrombus group
was 65.1% vs. 38.1% in the control group. The results showed that the presence of
MTHFR C677T mutation in ALL pediatric patients increases the risk of having
thrombosis by 3 folds (Table 8). These findings presented here confirm other studies
which reported the increase of thrombosis risk in patients with MTHFR C677T
mutation.
In agreement with our results, it was reported that MTHFR C677T mutation
is a risk factor for thrombosis in Indian patients (Kumari et al., 2014). In a case
control study done in Japan, it was found that MTHFR gene mutation was an
important risk factor for thrombosis when combined with other prothrombotic defect
(Fujimura et al., 2000). In Russia, it was reported that MTHFR C677T mutation was
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a risk factor for pulmonary artery thromboembolism (Avdonin et al., 2006). A study
done on 298 Chinese patients diagnosed with: deep venous thrombosis (DVT),
cerebral haemorrhage and cerebral infarction and coronary artery disease (CAD)
reported that MTHFR C677T mutation was an important risk factor for DVT and
cerebral infarction while the CAD was less associated with the mutation (Zheng et
al., 2000). Another study done on Chinese patients also reported that the MTHFR
C677T mutation was a risk factor for DVT (Guo et al., 2002). A meta-analysis
included 24 studies with 4048 controls and 2339 patients with thrombosis reported
that MTHFR C677T polymorphism was a risk factor for thrombosis in Chinese
population (Zhang et al., 2014). However, it was reported by Ramacciotti et al. 2003
that MTHFR C677T is not a significant risk factor for thrombosis. Where MTHFR
677T was found in 60.5% and 53.1% of control group and thrombus group
respectively. The 2 groups of patients were comparable to each other. Another study
done on Chinese patients reported the same results (Lu et al., 2002). In a case control
study done on Brazilian patients it was reported that the presence of MTHFR C677T
mutation was not a significant risk factor for thrombosis (Morelli et al., 2002)
Based on what was demonstrated in the current study, it is clear that MTHFR C677T
is an important risk factor for thrombosis in Egyptian pediatric ALL patients while
FV Leiden and PT G20210A are not.

4.9 Multiple prothrombotic Defects vs. Single and Risk of
Thrombosis
Our study showed that having more than one mutation didn’t have a
significant effect on thrombus incidence. This may be due to the small sample size of
the study group (63 patients) and studying 3 prothrombotic risk factors only. In
contrast to our results a German study showed a higher risk for thrombosis in
patients had more than 1 prothrombotic defect. The German study was done on 289
pediatric ALL patients treated on Berlin-Frankfurt-Munster (BFM) 90/95 protocol to
assess the risk of thrombosis in patients having prothrombotic defects (Nowak-Göttl
et al., 1999). This can be due to the large number of prothrombotic defects studied by
the German than in our study. In addition to FV Leiden, MTHFR C677T,
prothrombin G20210A mutations, they also studied the lipoprotein (a) concentration,
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deficiencies of anti-thrombin, protein S and protein C. The possibility to have
significant prothrombotic defects associated with risk of thrombosis will be higher in
case of studying larger number of parameters for each patient.

4.10 Prevalence of Inherited thrombophilia in Egyptian
Pediatric ALL patients
4.10.1 FV Leiden and PT G20210A prevalence in Egyptian Pediatric
ALL patients
The current study showed that FV Leiden prevalence in the control patients
was 14.3% and 1.6% for heterozygous and homozygous alleles respectively, while in
the thrombus patients was 15.9% and 1.6% for heterozygous and homozygous alleles
respectively. There was no significant difference in FV Leiden prevalence between
the patients with and without thrombosis. On the other hand, the PT G20210A
prevalence in the control patients and the thrombus patients was the same (3.2%) for
heterozygous and no homozygous was detected in both groups. To the best of our
knowledge, this is the 1st study on the prevalence of FV Leiden and prothrombin
G20210A in Egyptian pediatric ALL patients.

Association between ALL risk and FV Leiden and PT G20210A
mutation
The prevelance of FV leiden and PT G20210A mutation in our control
patients was comparable to the healthy Egyptian population. It was reported that the
prevelance of FV leiden and prothrombin G20210A mutations in healthy Egyptian
population was 16.5% and 1% respectively (Ulu et al., 2006), while ours was 15.9 %
and 3.2 % respectively. These results indicate that those 2 mutations could not be
associated with ALL risk. On contrary, it was reported in Iran that there was an
association between pediatric ALL risk and FV Leiden when compared with healthy
population (Rahimi et al., 2012), while the prothrombin G20210A mutation was not
a risk factor for pediatric ALL (Rahimi et al., 2013).
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4.10.2 MTHFR C677T point mutation in Egyptian pediatric ALL
patients
Our results showed that MTHFR C677T mutation prevalence in the control
patients was 28.6% and 9.5% for heterozygous and homozygous alleles respectively,
while in the thrombus patients was 57.1% and 7.9% for heterozygous and
homozygous alleles respectively. Several studies were done on Egyptian pediatric
ALL patients to assess the association between MTHFR polymorphism and several
toxicities. A study done to assess the high dose methotrexate toxicity in relation to
the prevalence of MTHFR C677T reported that it was 35%, 10% for heterozygous
and homozygous alleles, respectively (El-Khodary et al., 2012). While another study
reported MTHFR C677T prevalence as 27.5% and 40% for heterozygous and
homozygous alleles, respectively (Tantawy et al., 2010). There is a higher percentage
of homozygous allele reported by Tantawy et al when compared to EL-Khodary et
al. and the current study results.

Association between ALL Risk and MTHFR C677T
A previous study done on Egyptian population to evaluate the association of
MTHFR C677T on the pediatric ALL patient, recruited 88 ALL pediatric patients
and 311 healthy Egyptian individuals. The study reported prevalence of MTHFR
C677T of 47.7 % and 8% for heterozygous and homozygous allele in the ALL
patients, respectively. While the control healthy Egyptian patients showed MTHFR
prevalence of 43.4% and 6.4% for heterozygous and homozygous alleles,
respectively. The study concluded that MTHFR C677T polymorphism lack
protective effect against ALL risk (Kamel et al., 2007). On the other hand, the
present study results showed that the prevalence of MTHFR C677T in the control
group was 28.6 % and 9.5 % for heterozygous and homozygous alleles, respectively.
When we compare these results with the prevalence of MTHFR C677T in healthy
Egyptian population reported in Kamel et.al 2007 study we found that the healthy
Egyptian population had a higher incidence of MTHFR C677T than the ALL
patients. This may indicate a protective role for MTHFR C677T mutation against
ALL disease risk in Egyptian population. The current study results are in line with
other studies done on the MTHFR and its role in ALL risk. They suggested that
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increase in the MTHFR variants is associated with decreased risk of ALL, which
means that MTHFR variants had a protective role against ALL (Skibola et al., 1999;
Tone et al., 2001) .
A meta-analysis included 12 articles with 4146 controls and 1803 pediatric
ALL patients reported that MTHFR C677T mutation TT genotype had a protective
role against ALL in the Chinese children (Lin et al., 2014). Another meta-analysis
included 11 articles with 2,438 controls and 1,738 ALL patients found that MTHFR
polymorphism had a protective role from ALL (Xiao et al., 2014). In Brazil, a study
done on pediatric ALL patients found that MTHFR C677T polymorphism was
associated with a lower risk of ALL risk (Tone et al., 2001). The MTHFR
polymorphism protective role against ALL was explained by the following
mechanism. Leukemia arises commonly as a result of DNA deletions, inversions and
translocations in the genes responsible for the regulation of homeostasis or blood cell
development. It was reported that Folate deficiency is associated with misincorporation of Uracil into DNA. During uracil excision repair DNA double strand
breaks and lead to increase of chromosomal aberrations risk. These breaks could
contribute in increasing cancer susceptibility (Robien et al., 2003).
Normally, MTHFR enzyme directs 5, 10-methylenetetrahydrofolate towards
the synthesis of methionine at the expenses of DNA synthesis. Methylene- THF is a
methyl

donor,

which

converts

deoxyuracil

monophosphate

(dUMP)

to

deoxythymidine monophosphate (dTMP) in the presence of thymidylate synthase
enzyme. Increase of 5, 10 - methylene - THF plasma levels, leads to increasing of
dUMP conversion to dTMP. Which means a reduction in uracil mis incorporation
rate and optimal DNA synthesis (Figure 5) (Robien et al., 2003). In case of MTHFR
polymorphism, the decrease in the enzyme activity leads to decrease in the
conversion of 5, 10-methylene- THF to 5-methyl-THF and increase homocysteine
levels takes place. It is thought that MTHFR polymorphism can lead to optimal DNA
synthesis and less Uracil mis incorporation. This means less chromosomal aberration
during Uracil mis incorporation excision repair process (Robien et al., 2003).
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5. Conclusion
We found that MTHFR C677T is important risk factor for thrombosis in
Egyptian pediatric ALL patients. The presence of this polymorphism can increase the
risk of thrombosis 3 folds more than those patients who did not have the
polymorphism. In addition, the patients who are older than 10 years, on SR/HR
treatment protocol or in induction treatment phase are also at high risk of thrombosis
than others who are less than 10 years, treated on LR protocol or in any treatment
phase other than induction. Having one or more of those factors can increase the risk
of thrombosis in pediatric ALL patients. Those factors can be used as important
indicator for the risk of thrombosis in ALL patients. Using those factors will help in
the prediction of the thrombosis susceptibility for ALL patients and a prophylaxis
therapy can be given before having the thrombosis. Prediction of thrombosis is
crucial in enhancing the patient quality of life by preventing the complications
associated with the thrombosis that represent 10% of patients in our study. We also
found that there was no significant role for FV Leiden and PT G20210A in risk of
thrombosis.
Rechallenging patients with asparaginase as soon as possible after the
thrombus total recanalization took place is very essential as it can affect the patient
survival. We found that the EFS and the OS of the patients were the same in the 2
studied groups. That’s why we recommend restarting the L Asparaginase once the
thrombus is stationary or showed partial recanalization in order to keep the EFS and
the OS of thrombus patients as those without thrombosis. In addition, it was found
that there was no significant association between the thrombosis risk and the
combined mutations. Most probably this finding was due to the small sample size
and studying 3 prothrombotic factors only.
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6. Future recommendations
A routine screening for MTHFR polymorphism should be done in ALL new
patients before starting L-asparaginase and prednisolone to evaluate the risk of
thrombosis especially for those who have other risk factors such as age greater than
10 years or SR/HR patients. Further prospective study is recommended to evaluate
the importance of using anticoagulant as prophylaxis therapy in ALL pediatric
patients having high risk factors for thrombosis
Multicenter study with larger sample size is recommended to evaluate the
role of FV Leiden, PT G20210A as a thrombosis risk factor in Egyptian pediatric
ALL patients.
In the present study, we looked at genetic factors only, where other possible
risk factors such as protein S, protein C, homocysteine, anti- thrombin levels were
not evaluated. Evaluation of large number of factors will clarify whether the risk of
thrombosis was affected by the presence of combined risk factors or not.
A large case control study is recommended to evaluate the protective role of
MTHFR C677T against ALL.
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